Research Library

Two new bills introduced in the Texas Legislature could jeopardize the care received by Medicaid patients, writes Vivian Ho, the James A. Baker III Institute Chair in Health Economics. She explains why the legislation would weaken county-owned insurance plans and raise Texans’ tax bills.

In 2022, the nation faced fundamental questions about how we govern our economy and society — particularly how we formulate public policy. Here, we share 10 highlights of our work that illustrate our impact from the previous year.

Senior fellow Neal Lane remembers colleague Robert F. Curl.

"This pandemic and looming economic crisis will affect all of us ... The sooner we relearn how to set aside our differences and unite during this difficult moment, the stronger we will emerge from it," writes former Secretary James A. Baker, III.

Fellow Joe Barnes examines President Trump's foreign policies as his first 100 days in office come to a close.

James A. Baker, III, and George P. Shultz — both former secretaries of state and Treasury secretaries — offer "A Conservative Answer to Climate Change" in a commentary for The Wall Street Journal.

High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.

With the implementation of the Iran nuclear agreement, many Gulf Cooperative Council states now openly wonder whether U.S. support can still be relied upon, given the speed with which the U.S. government has engaged Iran in negotiation and diplomacy since 2013. This incomprehension may lead to further instability in the Middle East as the Gulf States continue to take increasingly unilateral action in Yemen and other regional conflict zones, fellow for the Middle East Kristian Coates Ulrichsen writes.

The deepening civil war in Yemen poses more challenges than solutions for Saudi Arabia, writes Middle East scholar Andrew Bowen.

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.